Moderate Interobserver Agreement for Glaucoma Software

Share this content:
Moderate Interobserver Agreement for Glaucoma Software
Moderate Interobserver Agreement for Glaucoma Software

MONDAY, March 6, 2017 (HealthDay News) -- There is moderate interobserver agreement among glaucoma specialists using two glaucoma progression software packages, according to a study published online Feb. 23 in JAMA Ophthalmology.

Javier Moreno-Montañés, M.D., Ph.D., from the Universidad de Navarra in Spain, and colleagues examined agreement in visual field (VF) and optical coherence tomography (OCT) software among five glaucoma specialists. The printout pages from VF and OCT progression software for 100 patients were randomized and evaluated by specialists; images were classified as having no progression, questionable progression, or progression. The specialists assessed whether the glaucoma damage had progressed and whether treatment change was needed using both software packages. The patients were reevaluated one month later in a different order to determine intraobserver reproducibility.

The researchers found that for VF and OCT software, intraobserver agreement was substantial to almost perfect (overall κ, 0.59 to 0.87 and 0.59 to 0.85, respectively). Among the five specialists, interobserver agreement was moderate for VF progression software (κ, 0.48) and for OCT progression software (κ, 0.52). In images classified as having no progression, interobserver agreement was substantial, while agreement was only fair in those classified as having questionable glaucoma progression or progression. Regarding questions about glaucoma progression and consideration about treatment changes, interobserver agreement was fair (κ, 0.39 and 0.39, respectively).

"These data suggest that these glaucoma progression software packages are insufficient to obtain high interobserver agreement in both devices except in patients with no progression," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »